North America T Cell Therapy Market to 2030 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America T Cell Therapy Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America T Cell Therapy Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Rising cancer incidence rates globally.
5.1.3 Increased funding for immunotherapy research.
5.1.4 Growing demand for personalized medicine.

5.2 Market Opportunities

5.2.1
5.2.2 Expansion into autoimmune disease treatments.
5.2.3 Advancements in genetic engineering technologies.
5.2.4 Collaborations with biotechnology firms.

5.3 Future Trends

5.3.1
5.3.2 Increased focus on CAR T-cell therapy.
5.3.3 Integration of AI in treatment development.
5.3.4 Shift towards combination therapies.

5.4 Impact of Drivers and Restraints

6. North America T Cell Therapy Market Regional Analysis

6.1 North America T Cell Therapy Market Overview

6.2 North America T Cell Therapy Market Revenue 2020-2030 (US$ Million)

6.3 North America T Cell Therapy Market Forecast Analysis

7. North America T Cell Therapy Market Analysis – by Modality

7.1 Research

7.1.1 Overview
7.1.2 Research: North America T Cell Therapy Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Commercialized

7.2.1 Overview
7.2.2 Commercialized: North America T Cell Therapy Market – Revenue and Forecast to 2031 (US$ Million)

8. North America T Cell Therapy Market Analysis – by Therapy Type

8.1 CAR T-cell Therapy

8.1.1 Overview
8.1.2 CAR T-cell Therapy: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

8.2 T-cell Receptor-based

8.2.1 Overview
8.2.2 T-cell Receptor-based: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

9. North America T Cell Therapy Market Analysis – by Indication

9.1 Hematologic Malignancies

9.1.1 Overview
9.1.2 T-cell Receptor-based: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

9.2 Solid Tumors

9.2.1 Overview
9.2.2 T-cell Receptor-based: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

10. North America T Cell Therapy Market – North America Analysis

10.1 North America

10.1.1 North America T Cell Therapy Market Breakdown, by Key Country, 2023 and 2030 (%)
10.1.1.1 North America T Cell Therapy Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.1.1 US: North America T Cell Therapy Market Breakdown, by Modality
10.1.1.1.2 US: North America T Cell Therapy Market Breakdown, by Therapy Type
10.1.1.1.3 US: North America T Cell Therapy Market Breakdown, by Indication

10.1.1.2 Canada: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Canada: North America T Cell Therapy Market Breakdown, by Modality
10.1.1.2.2 Canada: North America T Cell Therapy Market Breakdown, by Therapy Type
10.1.1.2.3 Canada: North America T Cell Therapy Market Breakdown, by Indication

10.1.1.3 Mexico : North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 Mexico : North America T Cell Therapy Market Breakdown, by Modality
10.1.1.3.2 Mexico : North America T Cell Therapy Market Breakdown, by Therapy Type
10.1.1.3.3 Mexico : North America T Cell Therapy Market Breakdown, by Indication

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America T Cell Therapy Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Bluebird Bio Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Bristol-Myers Squibb Co

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Cartesian Therapeutics Inc

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Gilead Sciences Inc

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Innovent Biologics Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Janssen Global Services LLC

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Novartis AG

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

14. Appendix

14.1 About Business Market Insights